Symbols / ISPC $0.22 +12.67%
ISPC Chart
About
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers worldwide. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. Its marketplace offers human biospecimens, including Biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; Solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and Hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types. The company serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 2.16M |
| Enterprise Value | -337.04K | Income | -11.53M | Sales | 3.35M |
| Book/sh | 0.31 | Cash/sh | 0.28 | Dividend Yield | — |
| Payout | 0.00% | Employees | 24 | IPO | — |
| P/E | — | Forward P/E | -0.28 | PEG | — |
| P/S | 0.65 | P/B | 0.71 | P/C | — |
| EV/EBITDA | 0.03 | EV/Sales | -0.10 | Quick Ratio | 0.51 |
| Current Ratio | 0.63 | Debt/Eq | 9.16 | LT Debt/Eq | — |
| EPS (ttm) | -8.81 | EPS next Y | -0.79 | EPS Growth | — |
| Revenue Growth | -96.00% | Earnings | 2024-08-06 09:00 | ROA | -74.84% |
| ROE | -296.20% | ROIC | — | Gross Margin | 21.55% |
| Oper. Margin | -26.55% | Profit Margin | 0.00% | Shs Outstand | 9.77M |
| Shs Float | 9.77M | Short Float | 9.62% | Short Ratio | 0.48 |
| Short Interest | — | 52W High | 3.18 | 52W Low | 0.18 |
| Beta | 1.88 | Avg Volume | 7.63M | Volume | 34.09M |
| Target Price | — | Recom | None | Prev Close | $0.20 |
| Price | $0.22 | Change | 12.67% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.22
Latest analyst target
3. DCF / Fair value
$-8.33
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.22
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2022-09-23 | main | EF Hutton | — → Buy | $4 |
| 2022-01-04 | init | Craig-Hallum | — → Buy | $20 |
| 2021-11-22 | main | EF Hutton | — → Buy | $12 |
- Why Is iSpecimen Stock (ISPC) Up Today 3/13/26? - TipRanks Fri, 13 Mar 2026 11
- Inside the race to collect 500 flu swabs for critical research - Stock Titan Mon, 16 Mar 2026 11
- iSpecimen (ISPC) Stock Rockets 43% After Hours — Here's Why It's Trending - Sahm Fri, 13 Mar 2026 07
- iSpecimen Faces Ongoing Shareholder Quorum Challenges for Meeting - The Globe and Mail Sat, 14 Mar 2026 21
- Q4 results ISPC iSpecimen NASDAQ Mar 2026 Mkt Closed: AI agent may shift outlook - Meyka hu, 12 Mar 2026 23
- New AI tool aims to speed scientists' access to human biospecimens - Stock Titan hu, 12 Mar 2026 20
- Stocks Under $1: TOON, ISPC, CXAI, EONR to Watch Now - marketscreener.com Mon, 16 Mar 2026 09
- iSpecimen Inc. Announces $5.5 Million Securities Purchase Agreement with Accredited Investors - Quiver Quantitative ue, 30 Dec 2025 08
- iSpecimen stock falls after $5.5 million preferred stock offering - Investing.com ue, 30 Dec 2025 08
- 12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm Sat, 14 Mar 2026 20
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga ue, 17 Mar 2026 12
- Repeated quorum shortfalls delay iSpecimen (NASDAQ: ISPC) 2025 annual meeting - Stock Titan Fri, 13 Mar 2026 21
- iSpecimen annual meeting adjourned again due to lack of quorum - Investing.com Fri, 13 Mar 2026 21
- 12 Health Care Stocks Moving In Friday's Intraday Session - Sahm Sat, 14 Mar 2026 20
- Online biospecimen marketplace raises $5.5M for marketing - Stock Titan ue, 30 Dec 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -9.98M | -8.75M | -8.80M | -4.95M |
| TotalUnusualItems | 0.00 | -900.75K | ||
| TotalUnusualItemsExcludingGoodwill | 0.00 | -900.75K | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -12.50M | -11.10M | -10.25M | -8.96M |
| ReconciledDepreciation | 2.29M | 2.12M | 1.21M | 1.00M |
| ReconciledCostOfRevenue | 5.30M | 4.82M | 4.76M | 5.25M |
| EBITDA | -9.98M | -8.75M | -8.80M | -5.86M |
| EBIT | -12.28M | -10.87M | -10.01M | -6.86M |
| NetInterestIncome | -175.94K | 108.97K | -69.62K | -2.09M |
| InterestExpense | 220.07K | 230.78K | 238.96K | 2.10M |
| InterestIncome | 44.13K | 339.75K | 169.34K | 11.40K |
| NormalizedIncome | -12.50M | -11.10M | -10.25M | -8.06M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -12.50M | -11.10M | -10.25M | -8.96M |
| TotalExpenses | 22.02M | 21.10M | 20.59M | 17.06M |
| TotalOperatingIncomeAsReported | -12.73M | -11.17M | -10.19M | -5.93M |
| DilutedAverageShares | 710.85K | 452.07K | 442.21K | 214.37K |
| BasicAverageShares | 710.85K | 452.07K | 442.21K | 214.37K |
| DilutedEPS | -17.58 | -24.55 | -23.20 | -41.80 |
| BasicEPS | -17.58 | -24.55 | -23.20 | -41.80 |
| DilutedNIAvailtoComStockholders | -12.50M | -11.10M | -10.25M | -8.96M |
| NetIncomeCommonStockholders | -12.50M | -11.10M | -10.25M | -8.96M |
| NetIncome | -12.50M | -11.10M | -10.25M | -8.96M |
| NetIncomeIncludingNoncontrollingInterests | -12.50M | -11.10M | -10.25M | -8.96M |
| NetIncomeContinuousOperations | -12.50M | -11.10M | -10.25M | -8.96M |
| PretaxIncome | -12.50M | -11.10M | -10.25M | -8.96M |
| OtherIncomeExpense | 406.18K | -39.10K | 9.78K | -945.28K |
| OtherNonOperatingIncomeExpenses | 406.18K | -39.10K | 9.78K | -44.53K |
| SpecialIncomeCharges | 0.00 | -2.21M | ||
| OtherSpecialCharges | 2.21M | |||
| GainOnSaleOfSecurity | 1.31M | |||
| NetNonOperatingInterestIncomeExpense | -175.94K | 108.97K | -69.62K | -2.09M |
| InterestExpenseNonOperating | 220.07K | 230.78K | 238.96K | 2.10M |
| InterestIncomeNonOperating | 44.13K | 339.75K | 169.34K | 11.40K |
| OperatingIncome | -12.73M | -11.17M | -10.19M | -5.93M |
| OperatingExpense | 16.72M | 16.28M | 15.83M | 11.81M |
| OtherOperatingExpenses | 537.89K | 1.03M | 801.12K | 573.91K |
| ResearchAndDevelopment | 3.53M | 3.57M | 2.66M | 1.84M |
| SellingGeneralAndAdministration | 12.65M | 11.68M | 12.37M | 9.40M |
| SellingAndMarketingExpense | 4.95M | 3.96M | 3.45M | 2.42M |
| GeneralAndAdministrativeExpense | 7.70M | 7.72M | 8.93M | 6.98M |
| OtherGandA | 7.70M | 7.72M | 8.93M | 6.98M |
| GrossProfit | 3.99M | 5.11M | 5.65M | 5.89M |
| CostOfRevenue | 5.30M | 4.82M | 4.76M | 5.25M |
| TotalRevenue | 9.29M | 9.93M | 10.40M | 11.14M |
| OperatingRevenue | 9.29M | 9.93M | 10.40M | 11.14M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 1.55K | 1.55K | 1.55K | 1.55K |
| OrdinarySharesNumber | 1.70M | 454.17K | 446.29K | 436.67K |
| ShareIssued | 1.70M | 455.72K | 447.84K | 438.22K |
| TotalDebt | 312.17K | 196.24K | 185.85K | 3.42M |
| TangibleBookValue | -2.02M | 2.51M | 15.81M | 27.08M |
| InvestedCapital | 3.31M | 9.74M | 20.31M | 33.21M |
| WorkingCapital | -2.18M | 2.19M | 15.39M | 30.44M |
| NetTangibleAssets | -2.02M | 2.51M | 15.81M | 27.08M |
| CapitalLeaseObligations | 312.17K | 196.24K | 185.85K | 0.00 |
| CommonStockEquity | 3.31M | 9.74M | 20.31M | 29.79M |
| TotalCapitalization | 3.31M | 9.74M | 20.31M | 33.21M |
| TotalEquityGrossMinorityInterest | 3.31M | 9.74M | 20.31M | 29.79M |
| StockholdersEquity | 3.31M | 9.74M | 20.31M | 29.79M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 840.00 | 0.00 | |
| OtherEquityAdjustments | 840.00 | |||
| TreasuryStock | 172.00 | 172.00 | 172.00 | 172.00 |
| RetainedEarnings | -71.86M | -59.36M | -48.27M | -38.02M |
| AdditionalPaidInCapital | 75.17M | 69.11M | 68.57M | 67.81M |
| CapitalStock | 170.00 | 45.00 | 892.00 | 873.00 |
| CommonStock | 170.00 | 45.00 | 892.00 | 873.00 |
| TotalLiabilitiesNetMinorityInterest | 6.04M | 6.08M | 4.31M | 5.93M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 268.80K | 29.13K | 27.40K | 3.42M |
| LongTermDebtAndCapitalLeaseObligation | 268.80K | 29.13K | 27.40K | 3.42M |
| LongTermCapitalLeaseObligation | 268.80K | 29.13K | 27.40K | 0.00 |
| LongTermDebt | 3.42M | |||
| CurrentLiabilities | 5.77M | 6.05M | 4.28M | 2.51M |
| CurrentDeferredLiabilities | 360.71K | 415.77K | 132.34K | 654.75K |
| CurrentDeferredRevenue | 360.71K | 415.77K | 132.34K | 654.75K |
| CurrentDebtAndCapitalLeaseObligation | 43.37K | 167.11K | 158.45K | |
| CurrentCapitalLeaseObligation | 43.37K | 167.11K | 158.45K | 0.00 |
| PayablesAndAccruedExpenses | 5.37M | 5.47M | 3.99M | 1.85M |
| CurrentAccruedExpenses | 1.17M | 1.54M | 1.53M | 1.02M |
| InterestPayable | 0.00 | 8.17K | ||
| Payables | 4.20M | 3.93M | 2.46M | 832.68K |
| AccountsPayable | 4.20M | 3.93M | 2.46M | 832.68K |
| TotalAssets | 9.35M | 15.82M | 24.62M | 35.72M |
| TotalNonCurrentAssets | 5.76M | 7.58M | 4.94M | 2.77M |
| NonCurrentPrepaidAssets | 12.10K | 27.60K | 27.60K | 27.60K |
| GoodwillAndOtherIntangibleAssets | 5.33M | 7.23M | 4.50M | 2.71M |
| OtherIntangibleAssets | 5.33M | 7.23M | 4.50M | 2.71M |
| NetPPE | 421.54K | 321.64K | 410.54K | 32.78K |
| AccumulatedDepreciation | -342.06K | -444.73K | -327.19K | -304.75K |
| GrossPPE | 763.61K | 766.38K | 737.73K | 337.54K |
| Leases | 12.65K | 68.47K | 60.44K | 24.93K |
| OtherProperties | 304.67K | 320.83K | 320.83K | 140.83K |
| MachineryFurnitureEquipment | 118.31K | 183.22K | 171.77K | 171.77K |
| BuildingsAndImprovements | 327.98K | 193.86K | 184.69K | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 3.59M | 8.24M | 19.68M | 32.95M |
| OtherCurrentAssets | 264.89K | 292.08K | 300.43K | 327.04K |
| PrepaidAssets | 327.04K | |||
| Receivables | 1.44M | 2.94M | 4.07M | 4.88M |
| OtherReceivables | 2.21M | 2.33M | 1.74M | |
| TaxesReceivable | 0.00 | 140.87K | 140.87K | |
| AccountsReceivable | 1.44M | 728.39K | 1.60M | 3.00M |
| AllowanceForDoubtfulAccountsReceivable | -620.43K | -520.90K | -231.00K | -269.17K |
| GrossAccountsReceivable | 2.07M | 1.25M | 1.83M | 3.27M |
| CashCashEquivalentsAndShortTermInvestments | 1.88M | 5.01M | 15.31M | 27.74M |
| OtherShortTermInvestments | 0.00 | 2.66M | 0.00 | |
| CashAndCashEquivalents | 1.88M | 2.34M | 15.31M | 27.74M |
| CashFinancial | 15.31M | 27.74M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -8.97M | -10.55M | -9.01M | -11.71M |
| RepaymentOfDebt | 0.00 | -3.50M | -3.00M | |
| IssuanceOfDebt | 0.00 | 4.00M | ||
| IssuanceOfCapitalStock | 1.89M | 0.00 | 0.00 | 41.50M |
| CapitalExpenditure | -709.83K | -4.74M | -3.19M | -1.04M |
| InterestPaidSupplementalData | 33.75K | 16.00K | 161.58K | 2.82M |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | ||
| EndCashPosition | 1.88M | 2.34M | 15.31M | 27.74M |
| BeginningCashPosition | 2.34M | 15.31M | 27.74M | 695.91K |
| ChangesInCash | -465.26K | -12.97M | -12.43M | 27.04M |
| FinancingCashFlow | 5.82M | 70.89K | -3.42M | 38.75M |
| CashFlowFromContinuingFinancingActivities | 5.82M | 70.89K | -3.42M | 38.75M |
| NetOtherFinancingCharges | -621.48K | -3.81M | ||
| ProceedsFromStockOptionExercised | 4.55M | 70.89K | 78.64K | 59.64K |
| NetCommonStockIssuance | 1.89M | 0.00 | 0.00 | 41.50M |
| CommonStockIssuance | 1.89M | 0.00 | 0.00 | 41.50M |
| NetIssuancePaymentsOfDebt | 0.00 | -3.50M | 1.00M | |
| NetLongTermDebtIssuance | 0.00 | -3.50M | 1.00M | |
| LongTermDebtPayments | 0.00 | -3.50M | -3.00M | |
| LongTermDebtIssuance | 0.00 | 4.00M | ||
| InvestingCashFlow | 1.98M | -7.23M | -3.19M | -1.04M |
| CashFlowFromContinuingInvestingActivities | 1.98M | -7.23M | -3.19M | -1.04M |
| NetInvestmentPurchaseAndSale | 2.69M | -2.48M | 0.00 | |
| SaleOfInvestment | 3.15M | 10.56M | 0.00 | |
| PurchaseOfInvestment | -460.93K | -13.04M | 0.00 | |
| NetIntangiblesPurchaseAndSale | -1.04M | |||
| PurchaseOfIntangibles | -1.04M | |||
| NetPPEPurchaseAndSale | -56.55K | -19.48K | -215.50K | -2.55K |
| PurchaseOfPPE | -56.55K | -19.48K | -215.50K | -2.55K |
| CapitalExpenditureReported | -653.29K | -4.73M | -2.98M | -1.04M |
| OperatingCashFlow | -8.26M | -5.81M | -5.82M | -10.67M |
| CashFlowFromContinuingOperatingActivities | -8.26M | -5.81M | -5.82M | -10.67M |
| ChangeInWorkingCapital | -502.67K | 2.59M | 2.35M | -5.28M |
| ChangeInOtherWorkingCapital | -55.06K | 283.44K | -522.41K | -218.51K |
| ChangeInOtherCurrentLiabilities | -120.20K | -155.96K | -147.28K | 0.00 |
| ChangeInOtherCurrentAssets | 127.01K | 157.19K | 148.43K | 0.00 |
| ChangeInPayablesAndAccruedExpense | -99.70K | 1.48M | 2.14M | -2.47M |
| ChangeInAccruedExpense | -371.82K | 9.37K | 513.27K | -1.51M |
| ChangeInInterestPayable | 0.00 | -8.17K | -1.71M | |
| ChangeInPayable | 272.12K | 1.47M | 1.63M | -959.75K |
| ChangeInAccountPayable | 272.12K | 1.47M | 1.63M | -959.75K |
| ChangeInPrepaidAssets | 42.69K | 8.36K | 26.60K | 90.89K |
| ChangeInReceivables | -397.40K | 820.61K | 709.18K | -2.68M |
| ChangesInAccountReceivables | -903.33K | 564.49K | 1.30M | -1.64M |
| OtherNonCashItems | -28.98K | -177.29K | 83.63K | 887.79K |
| StockBasedCompensation | 249.68K | 459.67K | 678.61K | 622.06K |
| AssetImpairmentCharge | 2.22M | 305.04K | 106.58K | 161.07K |
| DepreciationAmortizationDepletion | 2.29M | 2.12M | 1.21M | 1.00M |
| DepreciationAndAmortization | 2.29M | 2.12M | 1.21M | 1.00M |
| AmortizationCashFlow | 2.23M | 2.00M | 1.18M | 958.64K |
| AmortizationOfIntangibles | 2.23M | 2.00M | 1.18M | 958.64K |
| Depreciation | 65.71K | 117.54K | 22.43K | 45.36K |
| OperatingGainsLosses | 738.00 | 900.75K | ||
| GainLossOnInvestmentSecurities | 680.00 | -1.31M | ||
| GainLossOnSaleOfPPE | 58.00 | 0.00 | ||
| NetIncomeFromContinuingOperations | -12.50M | -11.10M | -10.25M | -8.96M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ISPC
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|